Cover Image
市場調查報告書

關注市場分析:茲卡病毒

Market Spotlight: Zika Virus

出版商 Datamonitor Healthcare 商品編碼 594575
出版日期 內容資訊 英文 23 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
關注市場分析:茲卡病毒 Market Spotlight: Zika Virus
出版日期: 2017年10月24日 內容資訊: 英文 23 Pages
簡介

本報告提供茲卡病毒的治療藥市場相關分析,疾病概要和患者數的變化、預測,目前的主要的調查治療方法,現在與開發中臨床實驗的進展與上市計劃,主要的治療藥的市場趨勢預測 (今後10年份),資本交易的動向等。

分析的要點

疾病的背景情況

治療方法

  • 疫苗
  • 治療藥

流行病學

開發平台上的醫藥品

授權合約、資產收購交易

  • GSK/NIH的'SAM'策略:茲卡病毒相關的成果獲得的可能性
  • Sanofi:與美軍共同的在非營利的茲卡病毒的研究

臨床實驗形勢

  • 贊助商數:各狀態
  • 贊助商數:各相位

相關分析

附錄

目錄
Product Code: DMKC0180743

This Market Spotlight report covers the Zika virus market, comprising key pipeline therapies, clinical trials, and licensing and acquisition deals.

Key Takeaways:

  • The Zika virus was first reported in continental South America in Brazil in May 2015. In February 2016, between 440,000 and 1,300,000 people were infected in Brazil. In the US, about 225 Zika virus cases were reported in August 2017. In addition, 554 cases were reported in people infected through local mosquito-borne transmission. Furthermore, autochthonous Zika virus transmission was reported in 25 countries in the Americas, Africa, and Asia.
  • In 2016, it was estimated that there were between 508 and 1,778 imported cases in Europe, particularly in France, Portugal, and Italy.
  • The majority of industry-sponsored drugs in active clinical development for Zika virus are in Phase I, with just a single product in Phase II.
  • Therapies in early-to-mid-stage development for Zika virus focus on the immune system and viral antigens. Candidates comprise DNA vaccines such as NIH's Zika Virus Vaccine and GeneOne's GLS-5700; Moderna's mRNA vaccine; Themis's recombinant viral vector vaccine; and Sanofi's purified inactivated Zika virus vaccine.
  • There were 12 licensing and asset acquisition activities involving Zika virus drugs during 2012-17, all of which occurred in either 2016 or 2017. The exclusive 2017 agreement between Emergent BioSolutions and Valneva worth $58.3m for the global rights to Valneva's Zika vaccine technology and ZIKV-VLA1601 was the largest deal during the 2012-17 period.
  • The distribution of clinical trials across Phases I-IV indicates that the majority of trials are occurring in Phase I, with just a single Phase II trial.
  • All industry-sponsored clinical trials are either ongoing or planned. GeneOne is the only company with more than one clinical trial currently ongoing. The only Phase II trial is being performed by Moderna Therapeutics.

TABLE OF CONTENTS

KEY TAKEAWAYS

DISEASE BACKGROUND

TREATMENT

  • Vaccines
  • Therapeutics

EPIDEMIOLOGY

PIPELINE DRUGS

LICENSING AND ASSET ACQUISITION DEALS

  • GSK/NIH 'SAM' Strategy May Reap Benefits Beyond Zika
  • Sanofi Teams With US Military On Zika, But Not For The Profits

CLINICAL TRIAL LANDSCAPE

  • Sponsors by status
  • Sponsors by phase

BIBLIOGRAPHY

APPENDIX

LIST OF FIGURES

  • Figure 1: Overview of pipeline drugs for Zika virus in the US
  • Figure 2: Pipeline drugs for Zika virus, by company
  • Figure 3: Pipeline drugs for Zika virus, by drug type
  • Figure 4: Pipeline drugs for Zika virus, by classifications
  • Figure 5: Licensing and asset acquisition deals in Zika virus, 2012-17
  • Figure 6: Clinical trials in Zika virus
  • Figure 7: Top 10 drugs for clinical trials in Zika virus
  • Figure 8: Top 10 companies for clinical trials in Zika virus
  • Figure 9: Zika virus trials status
  • Figure 10: Zika virus trials sponsors, by phase

LIST OF TABLES

  • Table 1: Recent epidemiological updates on Zika virus
  • Table 2: Zika virus cases timeline
  • Table 3: Pipeline drugs for Zika virus in the US
Back to Top